↓ Skip to main content

American Association for Cancer Research

Article Metrics

SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.

Overview of attention for article published in Cancer Research, October 2002
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet
wikipedia
1 Wikipedia page

Citations

dimensions_citation
165 Dimensions

Readers on

mendeley
57 Mendeley
citeulike
1 CiteULike
Title
SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Published in
Cancer Research, October 2002
Pubmed ID
Authors

Ashraf Dallol, Nancy Fernandes Da Silva, Paolo Viacava, John D Minna, Ivan Bieche, Eamonn R Maher, Farida Latif, John D. Minna, Eamonn R. Maher

Abstract

Slit2 plays a vital role in axon guidance by signaling through Robo receptors. Recent evidence suggests that Slit2 protein may function in other settings because human and Xenopus Slit2 has been shown to inhibit leukocyte chemotaxis. SLIT2 protein is a putative ligand for the ROBO receptors. We recently demonstrated that ROBO1 is inactivated by promoter region hypermethylation in <20% of human cancers; furthermore, tumor suppressor activity has not been shown. Thus, the importance of ROBO1 inactivation in human cancer is uncertain. Therefore, we investigated the status of SLIT2 located at 4p15.2 in lung and breast cancers. Although somatic SLIT2 mutations were not detected, epigenetic inactivation was common. SLIT2 promoter methylation was detected in 59% of breast cancer, 77% of non-small cell lung cancer, and 55% of small cell lung cancer cell lines. In these tumor lines, SLIT2 expression was restored by treatment with a demethylating agent. SLIT2 promoter methylation was detected in 43% of breast cancer, 53% of non-small cell lung cancer, and 36% of small cell lung cancer primary tumors. The majority of methylated tumors demonstrated allelic loss at 4p15.2. In addition, SLIT2 expression was down-regulated in methylated breast tumors, relative to normal control, as demonstrated by quantitative real-time reverse transcription-PCR. Overexpression of SLIT2 suppressed >70% of colony growth in each of three breast tumor lines (with either absent or low SLIT2 expression). Because SLIT2 is primarily a secreted protein, SLIT2-conditioned medium suppressed the growth of several breast cancer lines (with absent or weak SLIT2expression) by 26-51% but had no significant effect on a breast tumor cell line that expresses normal levels of SLIT2. These findings demonstrate that SLIT2 is frequently inactivated in lung and breast cancer by promoter region hypermethylation and allele loss and is an excellent candidate for the lung and breast tumor suppressor gene previously mapped to 4p15.2.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Hungary 1 2%
France 1 2%
United Kingdom 1 2%
Canada 1 2%
China 1 2%
Unknown 52 91%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 23%
Researcher 13 23%
Professor 6 11%
Student > Postgraduate 5 9%
Student > Bachelor 4 7%
Other 10 18%
Unknown 6 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 24 42%
Biochemistry, Genetics and Molecular Biology 11 19%
Medicine and Dentistry 10 18%
Veterinary Science and Veterinary Medicine 1 2%
Nursing and Health Professions 1 2%
Other 4 7%
Unknown 6 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2020.
All research outputs
#2,051,616
of 16,621,802 outputs
Outputs from Cancer Research
#1,643
of 14,847 outputs
Outputs of similar age
#38,329
of 294,864 outputs
Outputs of similar age from Cancer Research
#20
of 123 outputs
Altmetric has tracked 16,621,802 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,847 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,864 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.